Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.

ABSTRACT:

Objective

Progression prediction is a significant unmet need in people with progressive multiple sclerosis (pwPMS). Studies on glial fibrillary acidic protein (GFAP) have either been limited to single center with relapsing MS or were based solely on Expanded Disability Status Scale (EDSS), which limits its generalizability to state-of-the-art clinical settings and trials applying combined outcome parameters.

Methods

Serum GFAP and NfL (neurofilament light chain) were investigated in EmBioProMS participants with primary (PP) or secondary progressive MS. Six months confirmed disability progression (CDP) was defined using combined outcome parameters (EDSS, timed-25-foot walk test (T25FW), and nine-hole-peg-test (9HPT)).

Results

243 subjects (135 PPMS, 108 SPMS, age 55.5,

SUBMITTER: Abdelhak A 

PROVIDER: S-EPMC10863922 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature